Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 29;15:17588359231178125. doi: 10.1177/17588359231178125

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2023

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Trial design.

^aStage IIB or IIA that is either: N1 or N0 with: Grade 3 or Grade 2 with any of the following criteria: Ki67 ⩾ 20%, or Oncotype DX Breast Recurrence Score ⩾26, or categorized as high risk via Prosigna/PAM50, MammaPrint or EndoPredict EPclin Risk Score.

ctDNA, circulating tumor DNA; ctRNA, circulating tumor RNA; EBC, early nonmetastatic breast cancer; HER2−, human epidermal growth factor receptor 2 negative; HR+, hormone receptor positive; iDFS, invasive disease–free survival; NSAI, nonsteroidal aromatase inhibitor; OS, overall survival; PK, pharmacokinetic; PRO, patient-reported outcome; R, randomization; STEEP, Standardized Definitions for Efficacy End Points.